Dupilumab is now a safe treatment option for severe atopic eczema, especially in cases where other treatments have failed. There are few studies on dupilumab's safety and effectiveness in patients with kidney disease, despite known connections between nephrotic syndrome and atopic dermatitis. The quality of life is greatly impacted by pruritic disorders in patients with chronic kidney disease, highlighting the necessity for additional research to fully investigate dupilumab's potential in this population. Our case study emphasizes the significance of researching the safety of dupilumab in pediatric patients, particularly in light of its recent approval for use in children six years of age and older. We present a 6-month evaluation of the safety and effectiveness of dupilumab in a well-managed case of severe refractory atopic dermatitis in conjunction with nephrotic syndrome, and we strongly recommend the development of treatment guidelines.